Related Experiment Video

Updated: Jul 14, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1

Kenji Fujiwara1, Shuichi Kaneko, Shinichi Kakumu

  • 1Yokohama Rosai Hospital, Yokohama, Japan.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|June 19, 2007
PubMed

Insights

Double filtration plasmapheresis (DFPP) combined with interferon (IFN) significantly reduced viral load in difficult-to-treat chronic hepatitis C patients. This combination therapy offers a promising new treatment option for achieving sustained viral response.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis C (HCV) infection, particularly with difficult-to-treat genotypes like 1b and high viral loads, remains a significant clinical challenge.
  • Standard interferon (IFN) monotherapy or combination therapies often yield suboptimal sustained viral response rates in these patient populations.

Purpose of the Study:

  • To evaluate the efficacy and safety of combining double filtration plasmapheresis (DFPP) with interferon (IFN) therapy compared to IFN therapy alone.
  • To assess the impact of DFPP plus IFN on viral load reduction and sustained viral response in patients with high-load, difficult-to-treat genotype 1b chronic hepatitis C.

Main Methods:

  • A study involving 193 patients with chronic hepatitis C (genotype 1b, high viral load).
  • Patients received either IFN-alpha-2b monotherapy or combination therapies including ribavirin and pegylated interferon alpha-2b (PEG-IFN-alpha-2b).
  • A subset of patients received concomitant DFPP, immediately followed by IFN treatment, with up to five sessions in the first week.

Main Results:

  • The group receiving DFPP plus PEG-IFN-alpha-2b (n=30) showed significantly greater viral load reduction at 4 weeks compared to the non-DFPP group (n=74) (2.47 vs 1.52 log, P=0.010).
  • Sustained viral response rates were higher in the DFPP plus PEG-IFN-alpha-2b group (77.8%) versus the non-DFPP group (50.0%), including in re-treated patients.
  • Adverse events in DFPP-treated patients were mild and transient, occurring in 38.3%.

Conclusions:

  • Combination therapy with DFPP plus IFN effectively reduces viral load in the early stages of treatment for chronic hepatitis C.
  • This approach achieves a high sustained viral response rate, indicating its potential as a novel therapeutic strategy for difficult-to-treat chronic hepatitis C patients.
Abstract

More Related Videos

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration01:25

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...